Perhaps you should tell Zymo to put atacicept back in their published pipeline, if you feel that strongly - g -. Since they are not running the development program, it seems odd to treat it as a Zymo product on the board list, that's all.
BTW, I failed to jump clear of the Zymo stock wreck and have no financial or ego stake in bashing the company. A treatment for lupus would be a boon for patients, too.
Our mistake, that we discussed before making it, was to overpay for Zymo's pipeline when we were unconvinced that Recothrom would be very interesting. Hesitation is often justified (just not on RPRX!)
Market Data 
Markets 
AI
